Citing lackluster financial performance, IBM is halting development and sales of a product that uses its Watson AI software to help pharmaceutical companies discover new drugs, news outlet Stat reported on Thursday, citing a person familiar with the company’s internal decision-making. From the report: The decision to shut down sales of Watson for Drug Discovery marks the highest-profile retreat in the company’s effort to apply artificial intelligence to various areas of health care. Last year, the company scaled back on the hospital side of its business, and it’s struggled to develop a reliable tool to assist doctors in treating cancer patients. In a statement, an IBM spokesperson said, “We are focusing our resources within Watson Health to double down on the adjacent field of clinical development where we see an even greater market need for our data and AI capabilities.”
Further reading: IBM Pitched Its Watson Supercomputer as a Revolution in Cancer Care. It’s Nowhere Close (September 2017); IBM Watson Reportedly Recommended Cancer Treatments That Were ‘Unsafe and Incorrect’ (July 2018).
of this story at Slashdot.
Source:: Slashdot